Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: Data from the prospective, multicenter phase-II CLL-009 trial

A. Bühler, C. M. Wendtner, T. J. Kipps, L. Rassenti, G. A.M. Fraser, A. S. Michallet, P. Hillmen, J. Dürig, S. A. Gregory, M. Kalaycio, T. Aurran-Schleinitz, L. Trentin, J. G. Gribben, A. Chanan-Khan, B. Purse, J. Zhang, S. De Bedout, J. Mei, M. Hallek, S. Stilgenbauer

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: Data from the prospective, multicenter phase-II CLL-009 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences